Healthcare / BiotechnologyKOSDAQ
$1464.00
-58.00 (-3.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-7.8B · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-153.1%
↓Gross Margin
-100.3%
↓Debt/Equity
0.77
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.1%
FCF CAGR
—
FCF margin
-548.2%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.95B · net income $-10.93B · FCF $-10.69B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.95B | $1.95B | $1.93B | $1.12B | $1.02B |
| Net Income | $-10.93B | $-10.93B | $-9.54B | $-9.28B | $-8.34B |
| EBITDA | $-9.22B | $-9.22B | $-7.89B | $-7.68B | $-6.83B |
| EPS | -938.00 | -938.00 | -791.73 | -870.57 | -790.90 |
| Gross Margin | -100.3% | -100.3% | -71.9% | -165.2% | -170.9% |
| Operating Margin | -556.8% | -556.8% | -482.3% | -771.3% | -813.6% |
| Net Margin | -560.7% | -560.7% | -493.4% | -825.7% | -817.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.77 | 0.77 | 0.63 | 2.73 | 0.69 |
| Current Ratio | 1.88 | 1.88 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.69B | $-10.69B | $-7.82B | $-7.02B | $-8.62B |
| Returns | |||||
| ROE | -153.1% | -153.1% | -104.6% | -389.4% | -98.3% |
| Valuation | |||||
| P/B | 2.39 | 2.39 | 5.83 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 0.8% | 0.8% | 72.1% | 10.2% | — |
| EPS Growth | -18.5% | -18.5% | 9.1% | -10.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-57.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-791.73 → -938.00
Residual
-57.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.